They found that semaglutide was linked to a 28% reduction in major adverse cardiac events (12.3% in the placebo group had such events compared to 9.1% in the semaglutide group), as well as a 24% reduction in cardiovascular disease-related deaths for this subgroup of people with pre-existing heart failure, and a 19% reduction in deaths of any cause
It is also worth noting that our comparison with topiramate, which shares a weight loss property, may partly reflect topiramates poor real-world tolerability and compliance rather than a true pharmacological advantage of GLP1 RAs. However, he also stated that the overall signal is encouraging and justifies further investigation
Dec 132021Inorganic salts Semaglutide is a glucagon-like peptide (GLP-1) analog
GLP-1 medications can also cause tiredness, especially when treatment starts or doses increase, because of reduced calorie intake, dehydration, gastrointestinal side effects, and changes in glucose levels
This initial phase typically lasts for four weeks, proceeding cautiously to ensure the medication is well-tolerated while beginning to impact appetite control and blood sugar levels positively